Business Description
Covalon Technologies Ltd
NAICS : 541714
SIC : 8693
ISIN : CA22282D3022
Description
Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.02 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.26 | |||||
| Beneish M-Score | -2.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.1 | |||||
| 3-Year EBITDA Growth Rate | 10.7 | |||||
| 3-Year EPS without NRI Growth Rate | 15.7 | |||||
| 3-Year FCF Growth Rate | 8.8 | |||||
| 3-Year Book Growth Rate | 29.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.35 | |||||
| 9-Day RSI | 23.87 | |||||
| 14-Day RSI | 30.32 | |||||
| 6-1 Month Momentum % | -29.97 | |||||
| 12-1 Month Momentum % | -43.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.81 | |||||
| Quick Ratio | 3.25 | |||||
| Cash Ratio | 2.14 | |||||
| Days Inventory | 208.74 | |||||
| Days Sales Outstanding | 74.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.5 | |||||
| Shareholder Yield % | 5.59 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.91 | |||||
| Operating Margin % | -22.51 | |||||
| Net Margin % | -19.67 | |||||
| FCF Margin % | -15.16 | |||||
| ROE % | -23.89 | |||||
| ROA % | -18.74 | |||||
| ROIC % | -46.05 | |||||
| ROC (Joel Greenblatt) % | -54.73 | |||||
| ROCE % | -25.99 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.08 | |||||
| PB Ratio | 1.54 | |||||
| Price-to-Tangible-Book | 1.7 | |||||
| EV-to-EBIT | -3.58 | |||||
| EV-to-EBITDA | -4.13 | |||||
| EV-to-Revenue | 0.81 | |||||
| EV-to-FCF | -5.29 | |||||
| Price-to-Median-PS-Value | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 1.94 | |||||
| Price-to-Net-Cash | 7.41 | |||||
| Earnings Yield (Greenblatt) % | -27.93 | |||||
| FCF Yield % | -14.08 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers